Chat with us
Research Assistance
Online
  • Please enter your first name.

Middle East & Africa Cell And Gene Therapy Cdmo Market Size & Outlook

The cell and gene therapy cdmo market in Middle East & Africa is expected to reach a projected revenue of US$ 258.9 million by 2033. A compound annual growth rate of 14.2% is expected of Middle East & Africa cell and gene therapy cdmo market from 2025 to 2033.

  • HC Outsourcing
    • CMO/CDMO
      • Cell And Gene Therapy CDMO Market Outlook
Revenue, 2024 (US$M)
$78.3
Forecast, 2033 (US$M)
$258.9
CAGR, 2025 - 2033
14.2%
Report Coverage
Middle East & Africa
Middle East Africa Cell And Gene Therapy Cdmo Market, 2021-2033 (US$M)

This page contains premium content. Request sample data or start your free trial to explore Horizon.

  • ✔ Access to global market statistics
  • ✔ Access to company profiles
  • ✔ Free use-cases & research insights

No credit card required*

Global Market

Related Markets

Prism AI by Grand View ResearchFree to try

Ask a question about the cell and gene therapy cdmo market

Every figure cited from GVR research

MEA cell and gene therapy cdmo market highlights

  • The MEA cell and gene therapy cdmo market generated a revenue of USD 78.3 million in 2024.
  • The market is expected to grow at a CAGR of 14.2% from 2025 to 2033.
  • In terms of segment, pre-clinical was the largest revenue generating phase in 2024.
  • Pre-clinical is the most lucrative phase segment registering the fastest growth during the forecast period.
  • Country-wise, UAE is expected to register the highest CAGR from 2025 to 2033.


MEA data book summary

Market revenue in 2024USD 78.3 million
Market revenue in 2033USD 258.9 million
Growth rate14.2% (CAGR from 2025 to 2033)
Largest segmentPre-clinical
Fastest growing segmentPre-clinical
Historical data covered2021 - 2023
Base year for estimation2024
Forecast period covered2025 - 2033
Quantitative unitsRevenue in USD million
Market segmentationPre-clinical, Clinical
Key market players worldwideLonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc


Other key industry trends

  • In terms of revenue, MEA region accounted for 1.8% of the global cell and gene therapy cdmo market in 2024.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2033.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 4,989.5 million by 2033.

Middle Eastern countries such as South Africa, Saudi Arabia, the United Arab Emirates (UAE), and Kuwait are prospering economies. The cell & gene therapy CDMO market in the MEA is likely to grow steadily in the forthcoming period.

The increasing burden of diseases and the demand for drugs are some major factors contributing to market growth. In addition, the growing number of clinical trials is anticipated to boost the market over the forecast period.

According to the WHO International Clinical Trials Registry Platform (ICTRP), there were 861 clinical trials registered in Africa in 2022. Moreover, less competition between pharmaceutical companies in underdeveloped countries of the region is attracting various pharmaceutical startups, resulting in regional market growth.

No credit card required*

Publish Date: Sep 08, 2025

Customize the Report

20% free customization

Include
Countries, segments, points
Tailor
To your product definition
Extend
Deeper competitor detail
Or
A fully bespoke study

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Cell And Gene Therapy CDMO Market Companies

NameProfile# EmployeesHQWebsite
Novartis AG ADRView profile 76,057Lichtstrasse 35, Basel, Switzerland, 4056www.novartis.com
Lonza Group LtdView profile 18,000Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002www.lonza.com
Samsung Electronics Co LtdView profile 124,804129, Samsung-ro, Yeongtong-gu, Gyeonggi-do, Suwon-si, Korea, Republic of, 443-742www.samsung.com
Thermo Fisher Scientific IncView profile 122,000168 Third Avenue, Waltham, MA, United States, 02451www.thermofisher.com
Charles River Laboratories International IncView profile 21,400251 Ballardvale Street, Wilmington, MA, United States, 01887www.criver.com
OmniAb IncView profile 1065980 Horton Street, Suite 600, Emeryville, CA, United States, 94608www.omniab.com
Wuxi AppTec Co LtdView profile 41,116288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, China, People's Republic of, 200131www.wuxiapptec.com
AGC IncView profile 61,6711-5-1, Marunouchi, Chiyoda-ku, Tokyo, Japan, 100-8405www.agc.com
Catalent IncView profile 17,21914 Schoolhouse Road, Somerset, NJ, United States, 08873www.catalent.com
Rentschler Biopharma SEView profile 501-1000Laupheim, Baden-Wurttemberg, Germany, Europewww.rentschler-biopharma.com

Middle East & Africa Cell And Gene Therapy CDMO Market Outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cell And Gene Therapy CDMO Market Outlook will help companies and investors design strategic landscapes.


Pre-Clinical was the largest segment with a revenue share of 73.05% in 2024.

Horizon Databook has segmented the Middle East & Africa cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2021 to 2033.




Middle Eastern countries such as South Africa, Saudi Arabia, the United Arab Emirates (UAE), and Kuwait are prospering economies. The cell & gene therapy CDMO market in the MEA is likely to grow steadily in the forthcoming period.

The increasing burden of diseases and the demand for drugs are some major factors contributing to market growth. In addition, the growing number of clinical trials is anticipated to boost the market over the forecast period.

According to the WHO International Clinical Trials Registry Platform (ICTRP), there were 861 clinical trials registered in Africa in 2022. Moreover, less competition between pharmaceutical companies in underdeveloped countries of the region is attracting various pharmaceutical startups, resulting in regional market growth.

  • Middle East & Africa Cell And Gene Therapy Cdmo Market Phase Outlook (Revenue, USD Million , 2021-2033)
    • Pre-clinical
    • Clinical
  • Middle East & Africa Cell And Gene Therapy Cdmo Market Indication Outlook (Revenue, USD Million , 2021-2033)
    • Rare Diseases
    • Others
    • Oncology
    • Infectious Diseases
    • Neurological disorders
  • Middle East & Africa Cell And Gene Therapy Cdmo Market Product Type Outlook (Revenue, USD Million , 2021-2033)
    • Gene Therapy
    • Gene-Modified Cell Therapy
    • Cell Therapy

Reasons to subscribe to Cell And Gene Therapy CDMO Market Outlook databook

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Cell And Gene Therapy CDMO Market Outlook databook

  • Our clientele includes a mix of Cell And Gene Therapy CDMO Market Outlook companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa Cell And Gene Therapy CDMO Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa Cell And Gene Therapy CDMO Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.

Middle East Africa Cell And Gene Therapy Cdmo Market, 2021-2033 (US$M)

No Access Stack Chart

MEA cell and gene therapy cdmo market statistics, by phase, 2021-2033 (US$M)

No Access Pie Chart

MEA cell and gene therapy cdmo market statistics, by country, 2021-2033 (USD Million)

No Access

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more